UPDATE 1-Regeneron/Sanofi heart drug succeeds in major trial; Will insurers pay?
March 10, 2018 at 11:30 AM EST
March 10 (Reuters) - A potent, expensive cholesterol drug sold by Regeneron Pharmaceuticals and Sanofi significantly reduced major adverse heart events in a huge study presented on Saturday but it remains to be seen whether the new data will prompt insurers to pay for increased use of the medicine.